Leukemia News

Incorporation of next-generation sequencing into standard of practice will be required for patients with myelodysplastic syndrome and will impact all facets of care, according to a presenter at Chemotherapy Foundation Symposium.

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the outcome of patients with acute myeloid leukemia who received gilterintib with prior midostaurin or sorafenib therapy.

In this video, Alexander Edward Perl, MD, MS, discusses a study that showed patients with acute myeloid leukemia with genetic predictors of favorable-risk disease might still have poorer outcomes because of certain genetic mutations.

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the potential benefit of ceasing venetoclax-based therapy after remission in patients with acute myeloid leukemia.

Three individuals have been elected to American Society of Hematology’s executive committee.

The FDA approved asciminib for treatment of certain patients with chronic myeloid leukemia, according to a press release from the agent’s manufacturer.

Devimistat plus a modified standard-of-care chemotherapy regimen failed to extend OS among patients with metastatic pancreatic cancer, according to results of the randomized phase 3 AVENGER 500 trial released by the agent’s manufacturer.

Expanded use of chimeric antigen receptor T cells for cancer treatment requires that less expensive therapies be developed faster using multiple manufacturing models, according to an FDA official.

The FDA cleared an investigational new drug application for PRGN-3007, a chimeric antigen receptor T-cell therapy for patients with advanced hematologic malignancies or solid tumors that express receptor tyrosine kinase-like orphan receptor 1.

The sense of urgency surrounding the COVID-19 pandemic led to speedy development of several vaccines against the SARS-CoV-2 virus.